Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMVP Health Care Adakveo Coverage Policy | OpenPaye…
    Ask Trek AI about this page
    CurrentMVP Health CarePolicy N/A

    Adakveo (crizanlizumab-tmca) Coverage Criteria

    Customize your policy alerts

    Sign up for all MVP Health Care policy alerts

    Know when MVP Health Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical-benefit coverage and prior authorization for Adakveo (crizanlizumab-tmca) for members with sickle cell disease who are age 16 years and older when medical-necessity criteria are met.

    Policy Summary
    PayerMVP Health Care
    PolicyAdakveo (crizanlizumab-tmca) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective Date09/01/2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation of sickle cell disease, age 16 years or older, baseline vaso-occlusive crisis frequency, and failure, intolerance, or contraindication to hydroxyurea.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    16+ yearsMinimum member age
    6 monthsInitial approval
    Up to 1 yearExtension approval
    W0/W2, then q4wkAdministration

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Hydroxyurea
    Required prior therapy

    Coverage Criteria

    Initial Therapy Criteria

    Adakveo may be considered for coverage when all of the following criteria are met:

    ALL required conditions

    • Diagnosis and age: Chart notes confirm the diagnosis of sickle cell disease, and the member is at least 16 years of age.Age >= 16 years

      Submit documentation confirming the diagnosis and member age.

    • Baseline disease burden: Chart notes document the member's baseline vaso-occlusive crises.Number of crises within the past 1 year

      Document the number of vaso-occlusive crises during the preceding year.

    • Prior hydroxyurea therapy: Chart notes document failure, intolerance, or contraindication to hydroxyurea therapy.

    Continuation Therapy Criteria

    Extension requests may be approved for up to one year when current clinical documentation supports continued benefit.

    Continuation requirements

    • Improved member status: Current chart notes document improved member status.
    • Reduced vaso-occlusive crises: Current chart notes document a decrease in baseline vaso-occlusive crises.Decrease from baseline

    Coverage is excluded when the **indication, member age, dose, dosing frequency, or duration of therapy** falls outside FDA-approved package labeling.

    Codes Requiring Prior Authorization

    Codes Requiring Prior Authorization (covered under the medical benefit)HCPCSCovered
    J0791Injection, crizanlizumab-tmca, 5mg (Adakveo)

    Prior Authorization and Documentation

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Adakveo (crizanlizumab-tmca) when billed under the medical benefit. Submit the required clinical documentation with the request.

    • HCPCS J0791 — Injection, crizanlizumab-tmca, 5 mg (Adakveo)
    Step Therapy

    Hydroxyurea Prerequisite

    Before Adakveo coverage can be considered, documentation must establish that the member has failed, cannot tolerate, or has a contraindication to hydroxyurea therapy.

    • Document failure, intolerance, or contraindication to hydroxyurea therapy.

    Disease Background

    Sickle cell disease causes **rigid, sticky, sickle-shaped red blood cells** that can obstruct blood flow. These blockages may produce painful **vaso-occlusive crises**, which are intense episodes of pain associated with impaired blood flow from sickled red blood cells.

    Key Definitions

    Vaso-occlusive crises
    DefinitionIntense episodes of pain caused by blockages of blood flow associated with sickled red blood cells.

    Initial Approval Criteria

    Initial Approval Criteria

    Adakveo may be considered for coverage when all of the following criteria are met:

    ALL required conditions

    • Diagnosis and age: Chart notes confirm the diagnosis of sickle cell disease, and the member is at least 16 years of age.Age >= 16 years

      Submit documentation confirming the diagnosis and member age.

    • Baseline disease burden: Chart notes document the member's baseline vaso-occlusive crises.Number of crises within the past 1 year

      Document the number of vaso-occlusive crises during the preceding year.

    Extension Approval

    Extension Approval Criteria

    Extension requests may be approved for up to one year when current clinical documentation supports continued benefit.

    Extension requirements

    • Improved member status: Current chart notes document improved member status.
    • Decreased vaso-occlusive crises: Current chart notes document a decrease in baseline vaso-occlusive crises.Decrease from baseline

    Required Prior Therapy

    StepPrerequisite therapyRequirement before Adakveo coverage
    1HydroxyureaDocumented failure, intolerance, or contraindication to hydroxyurea therapy

    Administration Site and Schedule

    Billing Rule

    Administer at the required infusion schedule

    Adakveo is administered by intravenous infusion at an infusion center at week 0, week 2, and every 4 weeks thereafter.

    Policy Summary
    PayerMVP Health Care
    PolicyAdakveo (crizanlizumab-tmca) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective Date09/01/2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation of sickle cell disease, age 16 years or older, baseline vaso-occlusive crisis frequency, and failure, intolerance, or contraindication to hydroxyurea.
    SourceLink
    On This Page
    Coverage CriteriaCodes Requiring Prior AuthorizationPrior Authorization and DocumentationDisease BackgroundKey DefinitionsInitial Approval CriteriaExtension ApprovalRequired Prior TherapyAdministration Site and Schedule
    Documentation Required

    Initial Clinical Documentation

    Submit chart notes confirming the diagnosis of sickle cell disease, that the member is at least 16 years old, and the member’s baseline vaso-occlusive crisis history.

    • Confirmed diagnosis of sickle cell disease
    • Member is 16 years of age or older
    • Number of vaso-occlusive crises within the past one year
    Documentation Required

    Document Hydroxyurea History

    The clinical record must specifically describe the member’s hydroxyurea history and support the applicable reason Adakveo is being requested.

    • Document hydroxyurea failure, intolerance, or contraindication.
    • Include supporting chart notes or other clinical documentation.
    Documentation Required

    Extension Documentation

    Initial approval is for 6 months. Extension requests may be approved for up to one year only when current chart notes show improved member status and a decrease in baseline vaso-occlusive crises.

    • Provide current chart notes with each extension request.
    • Document improved member status.
    • Document decreased baseline vaso-occlusive crises.
    Denial Risk

    Use Within FDA-Approved Labeling

    Coverage is excluded when the requested use is outside FDA-approved package labeling.

    • Indication, age, dose, frequency of dosing, or duration of therapy outside FDA-approved labeling is not covered.
    Denial Risk

    Required Clinical Documentation

    Requests are at risk for denial when submitted documentation does not establish the required diagnosis, minimum age, baseline vaso-occlusive crisis history, or hydroxyurea treatment history.

    • Ensure chart notes address every required clinical criterion.
    • Include the number of baseline vaso-occlusive crises within the past one year.
    Prior hydroxyurea therapy: Chart notes document failure, intolerance, or contraindication to hydroxyurea therapy.